Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02868632
Title Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors New York University School of Medicine
Indications

pancreatic adenocarcinoma

Therapies

Tremelimumab

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.